983 related articles for article (PubMed ID: 29916012)
21. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
22. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier.
Wadhwa K; Chauhan P; Kumar S; Pahwa R; Verma R; Goyal R; Singh G; Sharma A; Rao N; Kaushik D
Oncol Res; 2024; 32(5):877-897. PubMed ID: 38686045
[TBL] [Abstract][Full Text] [Related]
23. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
24. Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy.
Nogueira-Librelotto DR; Codevilla CF; Farooqi A; Rolim CM
Curr Pharm Des; 2017; 23(3):454-466. PubMed ID: 27784246
[TBL] [Abstract][Full Text] [Related]
25. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.
Sabir F; Ismail R; Csoka I
Drug Discov Today; 2020 Jan; 25(1):185-194. PubMed ID: 31629966
[TBL] [Abstract][Full Text] [Related]
26. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Porru M; Zappavigna S; Salzano G; Luce A; Stoppacciaro A; Balestrieri ML; Artuso S; Lusa S; De Rosa G; Leonetti C; Caraglia M
Oncotarget; 2014 Nov; 5(21):10446-59. PubMed ID: 25431953
[TBL] [Abstract][Full Text] [Related]
27. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.
Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X
Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607
[TBL] [Abstract][Full Text] [Related]
28. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.
Stanimirovic DB; Sandhu JK; Costain WJ
BioDrugs; 2018 Dec; 32(6):547-559. PubMed ID: 30306341
[TBL] [Abstract][Full Text] [Related]
29. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor.
Wiley DT; Webster P; Gale A; Davis ME
Proc Natl Acad Sci U S A; 2013 May; 110(21):8662-7. PubMed ID: 23650374
[TBL] [Abstract][Full Text] [Related]
30. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
[TBL] [Abstract][Full Text] [Related]
31. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
[TBL] [Abstract][Full Text] [Related]
32. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.
Wen L; Tan Y; Dai S; Zhu Y; Meng T; Yang X; Liu Y; Liu X; Yuan H; Hu F
Drug Deliv; 2017 Nov; 24(1):1843-1855. PubMed ID: 29182025
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
34. Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models.
Sandbhor P; Goda J; Mohanty B; Chaudhari P; Dutt S; Banerjee R
Nanoscale; 2021 Dec; 14(1):108-126. PubMed ID: 34897360
[TBL] [Abstract][Full Text] [Related]
35. Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier.
Monaco I; Camorani S; Colecchia D; Locatelli E; Calandro P; Oudin A; Niclou S; Arra C; Chiariello M; Cerchia L; Comes Franchini M
J Med Chem; 2017 May; 60(10):4510-4516. PubMed ID: 28471660
[TBL] [Abstract][Full Text] [Related]
36. Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin.
Luck AN; Mason AB
Adv Drug Deliv Rev; 2013 Jul; 65(8):1012-9. PubMed ID: 23183585
[TBL] [Abstract][Full Text] [Related]
37. Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier.
Yan F; Wang Y; He S; Ku S; Gu W; Ye L
J Mater Sci Mater Med; 2013 Oct; 24(10):2371-9. PubMed ID: 23793566
[TBL] [Abstract][Full Text] [Related]
38. The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems.
Tortorella S; Karagiannis TC
Curr Drug Deliv; 2014; 11(4):427-43. PubMed ID: 24387131
[TBL] [Abstract][Full Text] [Related]
39. Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy.
Yang ZZ; Gao W; Liu YJ; Pang N; Qi XR
Mol Pharm; 2017 Apr; 14(4):1012-1022. PubMed ID: 28252970
[TBL] [Abstract][Full Text] [Related]
40. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.
Salzano G; Zappavigna S; Luce A; D'Onofrio N; Balestrieri ML; Grimaldi A; Lusa S; Ingrosso D; Artuso S; Porru M; Leonetti C; Caraglia M; De Rosa G
J Biomed Nanotechnol; 2016 Apr; 12(4):811-30. PubMed ID: 27301207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
